-+ 0.00%
-+ 0.00%
-+ 0.00%

Protalix BioTherapeutics Q2 EPS $0.05 Misses $0.12 Estimate, Sales $19.896M Beat $12.931M Estimate

Benzinga·08/12/2026 10:51:39
Listen to the news
Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.12 by 58.33 percent. The company reported quarterly sales of $19.896 million which beat the analyst consensus estimate of $12.931 million by 53.86 percent. This is a 27.07 percent increase over sales of $15.658 million the same period last year.